Long noncoding RNAs in cancer metastasis
Metastasis is a major contributor to cancer-associated deaths. It is characterized by a
multistep process that occurs through the acquisition of molecular and phenotypic changes …
multistep process that occurs through the acquisition of molecular and phenotypic changes …
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and …
M Guckenberger, Y Lievens, AB Bouma… - The Lancet …, 2020 - thelancet.com
Oligometastatic disease has been proposed as an intermediate state between localised and
systemically metastasised disease. In the absence of randomised phase 3 trials, early …
systemically metastasised disease. In the absence of randomised phase 3 trials, early …
[HTML][HTML] Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial
PURPOSE The oligometastatic paradigm hypothesizes that patients with a limited number of
metastases may achieve long-term disease control, or even cure, if all sites of disease can …
metastases may achieve long-term disease control, or even cure, if all sites of disease can …
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open …
Background The oligometastatic paradigm suggests that some patients with a limited
number of metastases might be cured if all lesions are eradicated. Evidence from …
number of metastases might be cured if all lesions are eradicated. Evidence from …
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
[HTML][HTML] Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
Y Lievens, M Guckenberger, D Gomez, M Hoyer… - Radiotherapy and …, 2020 - Elsevier
Background Recognizing the rapidly increasing interest and evidence in using metastasis-
directed radiotherapy (MDRT) for oligometastatic disease (OMD), ESTRO and ASTRO …
directed radiotherapy (MDRT) for oligometastatic disease (OMD), ESTRO and ASTRO …
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line …
DR Gomez, GR Blumenschein, JJ Lee… - The lancet …, 2016 - thelancet.com
Background Evidence from retrospective studies suggests that disease progression after first-
line chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at …
line chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at …
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S Novello, F Barlesi, R Califano, T Cufer… - Annals of …, 2016 - annalsofoncology.org
Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
Correction to:“Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
D Planchard, S Popat, K Kerr, S Novello… - Annals of …, 2019 - annalsofoncology.org
1. In KEYNOTE-189, patients with metastatic non-squamous NSCLC, PS 0-1, without
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …
[HTML][HTML] Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed …
The most recent version of the European Society for Medical Oncology (ESMO) Clinical
Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell …
Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell …